Breaking News Instant updates and real-time market news.

BERY

Berry Global

$66.49 /

+1.31 (+2.01%)

06:47
11/29/21
11/29
06:47
11/29/21
06:47

Ancora urges Berry Global to commit to review of strategic alternatives

Ancora Holdings Group announced that it has sent a letter to Berry Global Group, Inc.'s Board of Directors. The company said, "Ancora Holdings Group is a shareholder of Berry Global Group, with ownership of approximately one percent of the Company's outstanding shares. We believe Berry has a high-quality portfolio of packaging products and a unique value proposition to offer the global manufacturing sector. We also believe Berry has a capable management team that deserves credit for driving meaningful sales growth and earnings improvements in recent years. However, despite these tailwinds, Berry has been a chronic underperformer that perpetually trades at a significant discount to the broader market, relevant indices and packaging peers. In our view, it is time for the Board of Directors to take real action to address the impediments to value creation that have compounded at Berry. We deem Wednesday afternoon's announcement of $50 million in planned share repurchases to be an insult to investors. Not only is the size of the accelerated share repurchase transaction wholly insufficient, but the Board did not even increase its existing authorization. As total shareholder returns have lagged in recent years, the Board has repeatedly failed to establish an accretive capital allocation policy and seize opportunities to monetize non-core real estate assets. It is now necessary to initiate a comprehensive review of strategic alternatives, including a full sale or go-private transaction. We have spent significant energy and time analyzing Berry's operational and financial performance since Tom Salmon became Chief Executive Officer in February 2017. Mr. Salmon has presided over a 113.4% increase in annual revenues, an 83.8% increase in annual EBITDA and, most importantly, a 134.3% increase in diluted earnings per share. Regrettably, these results have been accompanied by a paltry 29.7% share price uptick during his nearly five-year tenure.1 Additionally, we remain concerned by Berry's acquisition track record and leverage philosophy. Shareholders have historically suffered as the Company, which was previously saddled with immense debt, pursued deals with excessively high leverage ratios, causing its shares to trade at an acute discount. But even now that the Company's leverage ratio is within its target range, its shares still continue to underperform the market. This suggests to us that Berry's persistent valuation discount is linked to the risk of the Board continuing to allocate capital to acquisitions, rather than simply being the result of the Company's leverage ratio. A credible capital allocation policy that prioritizes returning cash to shareholders could be one remedy for Berry's punishing valuation gap.We believe Ancora is not the only shareholder that feels the Board should commit to reviewing its existing strategy relative to alternatives. In recent months, we have had conversations with a number of fellow shareholders who expressed their own concerns about Berry's share price stagnation and valuation discount. Certain shareholders, including us, now believe they may be best served by seeing the Company sold to one of the many well-capitalized financial sponsors and strategic buyers in the marketplace. A review of relevant and comparable acquisitions indicates shareholders could receive $100 per share or more in value via a sale. It is unclear whether the current Board has a viable plan for unlocking that type of value on a standalone basis any time soon..As noted, we believe the Board needs to promptly commence a review of strategic alternatives. The review should be communicated publicly so that shareholders can see that the Board is taking its fiduciary duties seriously. We believe that a strong Board that is in tune with its shareholders would actively address the concerns of engaged shareholders. Playing hide-the-ball with information on the direction of the Company after a prolonged period of stagnation runs counter to what we believe are sound governance practices maintained by a well-functioning Board. First and foremost, we believe the Board should consider repurchasing additional shares with Berry's ample free cash flow and capital on hand. In light of the Company's strong profitability, it is particularly well-positioned to buy back stock at current levels. Not only would a large and ongoing repurchase program be accretive for Berry, but it would also send a strong message to investors that leadership has confidence in the business going forward. We suggest that the Board immediately announces an expansion of its repurchase authorization to $1 billion. Another logical step is a sale-leaseback transaction. If Berry is concerned about balance sheet flexibility and having sufficient cash to fund strategic growth, then it should consider funding share repurchases through a sale-leaseback transaction that will generate significant cash. We estimate Berry has up to $2 billion in real estate value currently tied up on its balance sheet, and that a transaction with the right buyer could provide the Company with nearly 20% of its market capitalization in cash. Seizing this opportunity would allow the Board to quickly upsize its $400 million "opportunistic" repurchase authorization to $1 billion or more in size, while still retaining capital for prudent investments. Lastly, we believe the Board owes it to long-suffering shareholders to evaluate a sale of the Company or a go-private transaction. Ancora, in particular, views this step as an absolute necessity given the public market's unwillingness to properly value Berry. Rather than taking action to aggressively combat the low valuation multiple, the Board has spent years allowing management to run the Company like a private business with an ultra-long-term investment horizon, translating to a lack of return of capital to shareholders. In light of the aforementioned factors, the Board should hire a qualified investment bank to run a market test. Our own analysis of comparable transactions indicates Berry could fetch a valuation of $100 per share or more via a sale."

OTHER BREAKING NEWS FROM THE FLY

Recommendations
Ouster price target lowered to $10 from $20 at Craig-Hallum » 09:35
01/24/22
01/24
09:35
01/24/22
09:35
OUST

Ouster

$3.47 /

-0.17 (-4.67%)

Craig-Hallum analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OUST Ouster
$3.47 /

-0.17 (-4.67%)

OUST Ouster
$3.47 /

-0.17 (-4.67%)

11/09/21 Citi
Ouster price target raised to $19 from $18 at Citi
11/09/21 Barclays
Ouster reinstated with an Overweight at Barclays
05/05/21 Barclays
Ouster initiated with an Overweight at Barclays
05/04/21 Baird
Baird starts 'differentiated' Ouster with Outperform, $16 target
OUST Ouster
$3.47 /

-0.17 (-4.67%)

OUST Ouster
$3.47 /

-0.17 (-4.67%)

OUST Ouster
$3.47 /

-0.17 (-4.67%)

OUST Ouster
$3.47 /

-0.17 (-4.67%)

Initiation
Context Therapeutics initiated with a Buy at ThinkEquity » 09:34
01/24/22
01/24
09:34
01/24/22
09:34
CNTX

Context Therapeutics

$2.09 /

+0.12 (+6.09%)

ThinkEquity analyst Ashok…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CNTX Context Therapeutics
$2.09 /

+0.12 (+6.09%)

  • 20
    Oct
CNTX Context Therapeutics
$2.09 /

+0.12 (+6.09%)

Recommendations
Prologis price target raised to $170 from $164 at RBC Capital » 09:33
01/24/22
01/24
09:33
01/24/22
09:33
PLD

Prologis

$155.55 /

+1.415 (+0.92%)

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PLD Prologis
$155.55 /

+1.415 (+0.92%)

PLD Prologis
$155.55 /

+1.415 (+0.92%)

01/21/22 Goldman Sachs
Prologis price target raised to $209 from $184 at Goldman Sachs
01/20/22 Baird
Prologis price target raised to $163 from $142 at Baird
01/19/22 Truist
Truist says Prologis' better than expected 2022 guidance points to strong demand
01/18/22 Truist
Prologis price target raised to $166 from $158 at Truist
PLD Prologis
$155.55 /

+1.415 (+0.92%)

PLD Prologis
$155.55 /

+1.415 (+0.92%)

Downgrade
Newmont cut to Sector Perform at Scotiabank after strong share price performance » 09:32
01/24/22
01/24
09:32
01/24/22
09:32
NEM

Newmont

$63.09 /

-0.74 (-1.16%)

As previously reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NEM Newmont
$63.09 /

-0.74 (-1.16%)

NEM Newmont
$63.09 /

-0.74 (-1.16%)

07:35 Today Scotiabank
Newmont downgraded to Sector Perform from Outperform at Scotiabank
01/07/22 National Bank
Newmont price target raised to C$98 from C$92 at National Bank
12/09/21 Canaccord
Newmont price target raised to $62 from $6 at Canaccord
11/23/21 National Bank
Newmont price target lowered to C$92 from C$95 at National Bank
NEM Newmont
$63.09 /

-0.74 (-1.16%)

NEM Newmont
$63.09 /

-0.74 (-1.16%)

NEM Newmont
$63.09 /

-0.74 (-1.16%)

Hot Stocks
Harbor Custom Development accepts bitcoin, cryptocurrencies for real estate » 09:32
01/24/22
01/24
09:32
01/24/22
09:32
HCDI

Harbor Custom Development

$2.24 /

-0.11 (-4.68%)

, BITCOIN

Bitcoin

/

+

, BTC

Bitcoin

/

+

, $BTC

Bitcoin

/

+

, $ETH

Ethereum

/

+

, $LTC

Litecoin

/

+

, $DOGE

Dogecoin

/

+

Harbor Custom Development…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HCDI Harbor Custom Development
$2.24 /

-0.11 (-4.68%)

BITCOIN Bitcoin
/

+

BTC Bitcoin
/

+

$BTC Bitcoin
/

+

$ETH Ethereum
/

+

$LTC Litecoin
/

+

$DOGE Dogecoin
/

+

HCDI Harbor Custom Development
$2.24 /

-0.11 (-4.68%)

BITCOIN Bitcoin
/

+

01/14/22 BTIG
BTIG 'incrementally more positive' on Riot Blockchain after CEO chat
09/08/21 Cowen
SEC's Coinbase action likely a broader crackdown on crypto lending, says Cowen
08/03/21 Craig-Hallum
Craig-Hallum bullish on Hut 8 Mining, initiates with a Buy
05/13/21 BTIG
BTIG sees Binance news as 'net positive' for Coinbase
BTC Bitcoin
/

+

01/14/22 BTIG
BTIG 'incrementally more positive' on Riot Blockchain after CEO chat
01/07/22 JPMorgan
JPMorgan sees greater acceptance for crypto, says Coinbase a buy
01/07/22 JPMorgan
JPMorgan sees greater acceptance for crypto, says Coinbase a buy
09/08/21 Cowen
SEC's Coinbase action likely a broader crackdown on crypto lending, says Cowen
$BTC Bitcoin
/

+

01/14/22 BTIG
BTIG 'incrementally more positive' on Riot Blockchain after CEO chat
01/07/22 JPMorgan
JPMorgan sees greater acceptance for crypto, says Coinbase a buy
01/07/22 JPMorgan
JPMorgan sees greater acceptance for crypto, says Coinbase a buy
09/08/21 Cowen
SEC's Coinbase action likely a broader crackdown on crypto lending, says Cowen
$ETH Ethereum
/

+

05/07/21 Argus
Ethan Allen upgraded to Buy from Hold at Argus
05/07/21 Argus
Ethan Allen upgraded to Buy from Hold at Argus
$LTC Litecoin
/

+

01/13/22 KeyBanc
LTC Properties upgraded to Overweight from Sector Weight at KeyBanc
06/03/21 Mizuho
LTC Properties downgraded to Underperform from Neutral at Mizuho
03/30/21 Capital One
LTC Properties downgraded to Equalweight from Overweight at Capital One
03/03/21 RBC Capital
LTC Properties price target raised to $38 from $33 at RBC Capital
$DOGE Dogecoin
/

+

HCDI Harbor Custom Development
$2.24 /

-0.11 (-4.68%)

BTC Bitcoin
/

+

$BTC Bitcoin
/

+

$ETH Ethereum
/

+

$LTC Litecoin
/

+

BITCOIN Bitcoin
/

+

BTC Bitcoin
/

+

$BTC Bitcoin
/

+

$ETH Ethereum
/

+

$LTC Litecoin
/

+

$DOGE Dogecoin
/

+

BITCOIN Bitcoin
/

+

BTC Bitcoin
/

+

$BTC Bitcoin
/

+

$ETH Ethereum
/

+

$LTC Litecoin
/

+

$DOGE Dogecoin
/

+

$ETH Ethereum
/

+

Recommendations
CF Industries price target raised to $75 from $73 at RBC Capital » 09:31
01/24/22
01/24
09:31
01/24/22
09:31
CF

CF Industries

$66.01 /

+1.685 (+2.62%)

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CF CF Industries
$66.01 /

+1.685 (+2.62%)

CF CF Industries
$66.01 /

+1.685 (+2.62%)

01/20/22 Stifel
Nutrien price target raised to $85, removed from 'Select List' at Stifel
01/13/22 Berenberg
CF Industries downgraded to Hold from Buy at Berenberg
01/11/22 Citi
CF Industries price target raised to $86 from $69 at Citi
12/17/21
Fly Intel: Top five analyst initiations
CF CF Industries
$66.01 /

+1.685 (+2.62%)

CF CF Industries
$66.01 /

+1.685 (+2.62%)

CF CF Industries
$66.01 /

+1.685 (+2.62%)

Downgrade
Yum China downgraded to Mixed from Positive at OTR Global » 09:31
01/24/22
01/24
09:31
01/24/22
09:31
YUMC

Yum China

$45.72 /

+0.04 (+0.09%)

OTR Global downgraded Yum…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
YUMC Yum China
$45.72 /

+0.04 (+0.09%)

YUMC Yum China
$45.72 /

+0.04 (+0.09%)

12/31/21 Morgan Stanley
Yum China price target lowered to $70 from $74 at Morgan Stanley
09/20/21 Stifel
Starbucks price target trimmed to $130 at Stifel after Yum China disclosures
09/15/21 Macquarie
Macquarie downgrades Yum China to sell on 'bumpy' sales recovery
09/15/21 Macquarie
Yum China downgraded to Underperform from Neutral at Macquarie
YUMC Yum China
$45.72 /

+0.04 (+0.09%)

YUMC Yum China
$45.72 /

+0.04 (+0.09%)

YUMC Yum China
$45.72 /

+0.04 (+0.09%)

Downgrade
Canada Goose downgraded to Mixed from Positive at OTR Global » 09:31
01/24/22
01/24
09:31
01/24/22
09:31
GOOS

Canada Goose

$30.10 /

-0.51 (-1.67%)

OTR Global downgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GOOS Canada Goose
$30.10 /

-0.51 (-1.67%)

GOOS Canada Goose
$30.10 /

-0.51 (-1.67%)

01/07/22 UBS
Canada Goose downgraded to Neutral from Buy at UBS
01/06/22 Barclays
Canada Goose upgraded to Overweight from Equal Weight at Barclays
01/05/22 TD Securities
Canada Goose upgraded to Buy at TD Securities ahead of Q3 report
01/05/22 TD Securities
Canada Goose upgraded to Buy from Hold at TD Securities
GOOS Canada Goose
$30.10 /

-0.51 (-1.67%)

GOOS Canada Goose
$30.10 /

-0.51 (-1.67%)

GOOS Canada Goose
$30.10 /

-0.51 (-1.67%)

Technical Analysis
Consumer Staples Sector SPDR: Pivot points » 09:29
01/24/22
01/24
09:29
01/24/22
09:29
XLP

Consumer Staples Sector SPDR

$75.95 /

+0.04 (+0.05%)

The following are the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XLP Consumer Staples Sector SPDR
$75.95 /

+0.04 (+0.05%)

07/19/21 Morgan Stanley
Morgan Stanley equity strategist upgrades Consumer Staples, downgrades Materials
XLP Consumer Staples Sector SPDR
$75.95 /

+0.04 (+0.05%)

XLP Consumer Staples Sector SPDR
$75.95 /

+0.04 (+0.05%)

Hot Stocks
Adial Pharmaceuticals receives notic of allowance on U.S. patent for AD04 » 09:27
01/24/22
01/24
09:27
01/24/22
09:27
ADIL

Adial Pharmaceuticals

$2.35 /

-0.195 (-7.68%)

Adial Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADIL Adial Pharmaceuticals
$2.35 /

-0.195 (-7.68%)

ADIL Adial Pharmaceuticals
$2.35 /

-0.195 (-7.68%)

10/13/21 Brookline
Brookline starts Adial Pharmaceuticals at Buy with $12 target
10/13/21 Brookline
Adial Pharmaceuticals initiated with a Buy at Brookline
08/26/21 Litchfield Hills
Adial Pharmaceuticals price target raised to $15 from $5 at Litchfield Hills
06/29/21 Litchfield Hills
Adial Pharmaceuticals initiated with a Buy at Litchfield Hills
  • 29
    Jun
ADIL Adial Pharmaceuticals
$2.35 /

-0.195 (-7.68%)

Recommendations
Wintrust Financial price target raised to $125 from $105 at Truist » 09:26
01/24/22
01/24
09:26
01/24/22
09:26
WTFC

Wintrust Financial

$97.35 /

-2.015 (-2.03%)

Truist analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WTFC Wintrust Financial
$97.35 /

-2.015 (-2.03%)

WTFC Wintrust Financial
$97.35 /

-2.015 (-2.03%)

01/21/22 RBC Capital
Wintrust Financial price target raised to $122 from $110 at RBC Capital
01/21/22 Raymond James
Wintrust Financial price target raised to $127 from $112 at Raymond James
01/20/22 Wedbush
Wintrust Financial price target raised to $115 from $110 at Wedbush
11/29/21 Raymond James
Wintrust Financial price target raised to $112 from $108 at Raymond James
WTFC Wintrust Financial
$97.35 /

-2.015 (-2.03%)

WTFC Wintrust Financial
$97.35 /

-2.015 (-2.03%)

Initiation
Exelon initiated with a Buy at Spin-Off Research » 09:24
01/24/22
01/24
09:24
01/24/22
09:24
EXC

Exelon

$56.80 /

-0.18 (-0.32%)

Spin-Off Research…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EXC Exelon
$56.80 /

-0.18 (-0.32%)

EXC Exelon
$56.80 /

-0.18 (-0.32%)

01/13/22 KeyBanc
Exelon upgraded to Overweight from Sector Weight at KeyBanc
01/04/22 RBC Capital
Exelon price target raised to $60 from $51 at RBC Capital
01/03/22 Mizuho
Exelon downgraded to Neutral from Buy at Mizuho
10/15/21 Mizuho
Exelon price target raised to $55 from $53 at Mizuho
EXC Exelon
$56.80 /

-0.18 (-0.32%)

Hot Stocks
Biotricity receives FDA 510-k clearance for Biotres cardiac monitoring device » 09:22
01/24/22
01/24
09:22
01/24/22
09:22
BTCY

Biotricity

$3.23 /

+0.04 (+1.25%)

Biotricity reported it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BTCY Biotricity
$3.23 /

+0.04 (+1.25%)

BTCY Biotricity
$3.23 /

+0.04 (+1.25%)

11/23/21 H.C. Wainwright
Biotricity initiated with a Buy at H.C. Wainwright
07/01/21 Northland
Biotricity initiated with an Outperform at Northland
BTCY Biotricity
$3.23 /

+0.04 (+1.25%)

Technical Analysis
Health Care Select Sector SPDR: Pivot points » 09:22
01/24/22
01/24
09:22
01/24/22
09:22
XLV

Health Care Select Sector SPDR

$129.43 /

-1.42 (-1.09%)

The following are the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XLV Health Care Select Sector SPDR
$129.43 /

-1.42 (-1.09%)

XLV Health Care Select Sector SPDR
$129.43 /

-1.42 (-1.09%)

Hot Stocks
Halliburton: North America frack work sold out  09:22
01/24/22
01/24
09:22
01/24/22
09:22
HAL

Halliburton

$27.55 /

-0.58 (-2.06%)

 
ShowHide Related Items >><<
HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

01/13/22 JPMorgan
Baker Hughes downgraded to Neutral from Overweight at JPMorgan
01/13/22 JPMorgan
Halliburton upgraded to Overweight from Neutral at JPMorgan
01/04/22 Morgan Stanley
Halliburton upgraded to Overweight at Morgan Stanley on cash return expectations
01/04/22 Morgan Stanley
Halliburton upgraded to Overweight from Equal Weight at Morgan Stanley
HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

Hot Stocks
Halliburton starting 2022 a lot higher despite typical Q1 seasonality  09:20
01/24/22
01/24
09:20
01/24/22
09:20
HAL

Halliburton

$27.55 /

-0.58 (-2.06%)

 
ShowHide Related Items >><<
HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

01/13/22 JPMorgan
Baker Hughes downgraded to Neutral from Overweight at JPMorgan
01/13/22 JPMorgan
Halliburton upgraded to Overweight from Neutral at JPMorgan
01/04/22 Morgan Stanley
Halliburton upgraded to Overweight at Morgan Stanley on cash return expectations
01/04/22 Morgan Stanley
Halliburton upgraded to Overweight from Equal Weight at Morgan Stanley
HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

HAL Halliburton
$27.55 /

-0.58 (-2.06%)

Hot Stocks
GenTech's Fizzique receives initial order from T&A Distribution » 09:20
01/24/22
01/24
09:20
01/24/22
09:20
GTEH

GenTech

/

+

GenTech Holdings received…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GTEH GenTech
/

+

GTEH GenTech
/

+

Initiation
Element Solutions initiated with a Buy at CL King » 09:19
01/24/22
01/24
09:19
01/24/22
09:19
ESI

Element Solutions

$22.94 /

-0.41 (-1.76%)

CL King analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ESI Element Solutions
$22.94 /

-0.41 (-1.76%)

10/12/21 Mizuho
Mizuho sees multiple secular tailwinds in Electronics / Semi materials sector
10/12/21 Mizuho
Element Solutions initiated with a Buy at Mizuho
07/06/21 UBS
UBS downgrades Atotech on takeout, says buy Element Solutions
06/15/21 Loop Capital
Element Solutions price target raised to $29 from $27 at Loop Capital
ESI Element Solutions
$22.94 /

-0.41 (-1.76%)

Recommendations
Piper still bullish on Arcturus after 'strong' booster data » 09:18
01/24/22
01/24
09:18
01/24/22
09:18
ARCT

Arcturus Therapeutics

$24.60 /

-0.78 (-3.07%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ARCT Arcturus Therapeutics
$24.60 /

-0.78 (-3.07%)

ARCT Arcturus Therapeutics
$24.60 /

-0.78 (-3.07%)

12/16/21 Piper Sandler
Arcturus data shows 'legit player' in COVID vaccines, says Piper Sandler
12/09/21 Piper Sandler
December kicks off catalyst rich month for Arcturus Therapeutics, says Piper
11/16/21 Cantor Fitzgerald
Arcturus Therapeutics price target raised to $93 from $85 at Cantor Fitzgerald
11/09/21 Barclays
Arcturus Therapeutics price target lowered to $31 from $46 at Barclays
ARCT Arcturus Therapeutics
$24.60 /

-0.78 (-3.07%)

ARCT Arcturus Therapeutics
$24.60 /

-0.78 (-3.07%)

Hot Stocks
Kreatorhood selects Nuvei to power payments for digital content creators » 09:18
01/24/22
01/24
09:18
01/24/22
09:18
NVEI

Nuvei

$59.55 /

-3.475 (-5.51%)

Nuvei Corporation…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NVEI Nuvei
$59.55 /

-3.475 (-5.51%)

NVEI Nuvei
$59.55 /

-3.475 (-5.51%)

01/11/22 Goldman Sachs
Nuvei initiated with a Buy at Goldman Sachs
01/02/22 BMO Capital
PayPal upgraded to Outperform from Market Perform at BMO Capital
12/09/21 Keefe Bruyette
Keefe Bruyette doesn't see 'smoking gun' in Nuvei short report
12/09/21
Fly Intel: Top five analyst upgrades
NVEI Nuvei
$59.55 /

-3.475 (-5.51%)

  • 06
    Oct
NVEI Nuvei
$59.55 /

-3.475 (-5.51%)

NVEI Nuvei
$59.55 /

-3.475 (-5.51%)

NVEI Nuvei
$59.55 /

-3.475 (-5.51%)

Hot Stocks
Petros Pharmaceuticals enters partnership to produce Stendra in U.S. » 09:17
01/24/22
01/24
09:17
01/24/22
09:17
PTPI

Petros Pharmaceuticals

$1.50 /

-0.155 (-9.37%)

Petros Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PTPI Petros Pharmaceuticals
$1.50 /

-0.155 (-9.37%)

PTPI Petros Pharmaceuticals
$1.50 /

-0.155 (-9.37%)

PTPI Petros Pharmaceuticals
$1.50 /

-0.155 (-9.37%)

Hot Stocks
NCS Multistage wins patent infringement case against Nine Energy Service » 09:17
01/24/22
01/24
09:17
01/24/22
09:17
NCSM

NCS Multistage

$38.50 /

-3 (-7.23%)

, NINE

Nine Energy Service

$1.10 /

+0.02 (+1.85%)

NCS Multistage Holdings…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NINE Nine Energy Service
$1.10 /

+0.02 (+1.85%)

Periodicals
Trian has not contacted Unilever on potential investment, CNBC reports » 09:16
01/24/22
01/24
09:16
01/24/22
09:16
UL

Unilever

$49.30 /

-0.125 (-0.25%)

Nelson Peltz's Trian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UL Unilever
$49.30 /

-0.125 (-0.25%)

UL Unilever
$49.30 /

-0.125 (-0.25%)

08:04 Today Jefferies
Trian involvement at Unilever likely 'materially positive,' says Jefferies
01/19/22 Societe Generale
Societe Generale double upgrades Unilever after selloff on 'clumsy' bid
01/19/22 Societe Generale
Unilever upgraded to Buy from Sell at Societe Generale
01/17/22 Bernstein
Unilever downgraded to Underperform from Market Perform at Bernstein
UL Unilever
$49.30 /

-0.125 (-0.25%)

UL Unilever
$49.30 /

-0.125 (-0.25%)

UL Unilever
$49.30 /

-0.125 (-0.25%)

Initiation
Panasonic initiated with a Neutral at Goldman Sachs » 09:15
01/24/22
01/24
09:15
01/24/22
09:15
PCRFY

Panasonic

$11.36 /

+0.06 (+0.53%)

Goldman Sachs analyst Ryo…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PCRFY Panasonic
$11.36 /

+0.06 (+0.53%)

PCRFY Panasonic
$11.36 /

+0.06 (+0.53%)

10/08/21 Mizuho
Panasonic upgraded to Buy from Neutral at Mizuho
PCRFY Panasonic
$11.36 /

+0.06 (+0.53%)

Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points » 09:15
01/24/22
01/24
09:15
01/24/22
09:15
IWM

iShares Trust Russell 2000 Index Fund

$197.03 /

-3.71 (-1.85%)

The following are the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IWM iShares Trust Russell 2000 Index Fund
$197.03 /

-3.71 (-1.85%)

IWM iShares Trust Russell 2000 Index Fund
$197.03 /

-3.71 (-1.85%)

03/15/21 Morgan Stanley
Morgan Stanley equity strategist downgrades small cap stocks
IWM iShares Trust Russell 2000 Index Fund
$197.03 /

-3.71 (-1.85%)

IWM iShares Trust Russell 2000 Index Fund
$197.03 /

-3.71 (-1.85%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.